UN 
- $120 million allocated to HPV vaccine deployment in Kenya by WHO and PATH
- Target of 85% coverage of eligible girls by December 2026
- Kenya currently reports less than 35% HPV vaccination coverage among target age group
Kenya has struggled to scale up HPV vaccination since introduction in 2019, with the Ministry of Health estimating current coverage below 35% for girls aged 9-14 years. The WHO-PATH partnership seeks to close this gap and deliver on Sustainable Development Goal 3 (Good Health & Well-being) by reducing future cervical cancer cases—currently the second most common cancer among women in Kenya.
The $120 million funding package, announced in Nairobi in May 2024, will finance vaccine procurement, cold chain improvements, advocacy, and capacity building for local healthcare workers. PATH states that measurable progress, such as quarterly vaccination rates and regional breakdowns, will be published openly to monitor delivery against the 85% coverage pledge for 2026. This approach, PATH asserts, is designed to address both supply-side bottlenecks and community hesitancy.
Independent analysts have noted that previous pledges in African vaccination campaigns have sometimes fallen short on delivery, citing logistical challenges and uneven access in rural areas. WHO and PATH aim to counter skepticism by integrating digital tracking and third-party audits, promising transparent reporting to minimize risks of greenwashing and ensure genuine impact.
Frequently Asked Questions
What is the objective of the WHO and PATH HPV vaccination drive in Kenya?
The main goal is to vaccinate at least 85% of Kenyan girls aged 9 to 14 against HPV by the end of 2026. This is intended to lower the incidence of cervical cancer, which is a leading cause of cancer deaths among Kenyan women. The $120 million funding supports procurement, infrastructure, and outreach efforts.
How will progress towards the 85% target be tracked and reported?
PATH and WHO plan to publicly release quarterly updates on vaccination rates, including regional and demographic breakdowns. They have pledged to use digital health tools and third-party audits to provide transparent, verifiable data on coverage and address concerns of over-reporting or greenwashing.
What challenges could affect delivery of the vaccination program?
Key challenges in Kenya include vaccine supply logistics, inadequate cold chain capacity, community hesitancy, and reaching girls in remote areas. The funding package earmarks significant funds for infrastructure and training, but success will depend on execution and sustained political and community support.
Frequently Asked Questions
What is the goal of the WHO and PATH HPV vaccination program in Kenya?
The goal is to vaccinate at least 85% of Kenyan girls aged 9 to 14 against HPV by the end of 2026 to reduce cervical cancer rates.
How much funding have WHO and PATH committed to Kenya’s HPV vaccine rollout?
WHO and PATH have committed $120 million to Kenya’s HPV vaccination program.
What is Kenya’s current HPV vaccination coverage among girls aged 9-14?
Kenya currently reports less than 35% HPV vaccination coverage among girls aged 9-14.
How will the progress of the HPV vaccination campaign in Kenya be tracked?
Progress will be tracked through quarterly public updates on vaccination rates, including regional breakdowns, using digital health tools and third-party audits.
What challenges could impact the success of the HPV vaccination rollout in Kenya?
Challenges include vaccine supply logistics, inadequate cold chain capacity, community hesitancy, and reaching girls in remote areas.
